US Stock Insider Trading | Septerna disclosed 5 insider transactions on March 4

K-LinePoet · 2026-03-31T12:33:48+00:00

Septerna disclosed on March 4, 2026, that executive Shaikhly Samira conducted multiple transactions on March 2, including the purchase of 16,700 shares and 53,700 shares, as well as the sale of 66,400 shares and 4,090 shares. The company is a biotechnology firm focused on G protein-coupled receptor drug discovery.

K-LinePoet

2026-03-31 12:33:48

Abstract generation in progress

On March 4, 2026, Septerna (SEPN) disclosed five company insider transactions. Executive Shaikhly Samira sold 66,400 shares on March 2, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price Per Share/USD	Total Value/USD
March 4, 2026	Executive	Shaikhly Samira	March 2, 2026	Buy	16,700	2.76	46,200
March 4, 2026	Executive	Shaikhly Samira	March 2, 2026	Buy	53,700	1.55	83,300
March 4, 2026	Executive	Shaikhly Samira	March 2, 2026	Sell	66,400	28.14	1.8673M
March 4, 2026	Executive	Shaikhly Samira	March 2, 2026	Sell	4090	27.51	112,500
February 20, 2026	Executive	Bhatt Elizabeth	February 18, 2026	Buy	4000	6.81	27,200
February 20, 2026	Executive	Bhatt Elizabeth	February 18, 2026	Sell	2200	28.46	62,600
February 20, 2026	Executive	Bhatt Elizabeth	February 18, 2026	Sell	1800	29.58	53,200
November 13, 2025	Executive	Long Daniel D.	November 10, 2025	Sell	3501	18.06	63,200
August 19, 2025	Executive	Klein Uwe	August 18, 2025	Buy	7621	6.81	51,900
August 19, 2025	Executive	Klein Uwe	August 18, 2025	Buy	15,400	2.76	42,500

[Company Profile]

Septerna, Inc. was incorporated in Delaware in December 2019 under the name GPCR NewCo, Inc. In June 2021, they changed their name to Septerna, Inc. The company is a clinical-stage biotechnology company that is ushering in a new era of discovery of oral small-molecule drugs targeting G protein-coupled receptors (GPCR). Its engine is powered by its proprietary Native Complex PlatformTM. Its industrial-scale platform is designed to unlock the full potential of GPCR therapies and to discover and develop its deep candidate product pipeline, initially focusing on patients in three therapeutic areas: endocrinology, immunology, and inflammation, as well as metabolic diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.